Trial results

A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

NCT07284511 on ClinicalTrials.gov · last registry update 2026-05-27

Recruiting now, toward 105 participants. Due to report January 2028, alongside 22 other tracked readouts that quarter. Primary outcome, as filed: Daytime Time-in-Range. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

RECRUITING

Phase

P2/P3

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Sponsor type

Other

Enrollment

105

Started

2026-05-19

Primary completion

2028-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Daytime Time-in-Range

Conditions studied

Type 1 Diabetes · Type 1 Diabetes Mellitus · T1D · T1DM · T1DM - Type 1 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.